Recurrent Pancreatic Cancer

Proton Beam Therapy May Improve Outcomes for Esophageal Cancer (01-23-2017)

Currently a standard treatment for several gastrointestinal cancers (GI) combines the use of chemotherapy and radiation followed by surgical resection. Radiation may be part of the treatment strategy for select cancers of the esophagus, anus, rectum,... Continue Reading

Pancreatic Cancer Cells Find Unique Fuel Sources to Keep from Starving (08-17-2016)

Pancreatic cancer cells avert starvation in dense tumors by ordering nearby support cells to supply them with an alternative source of nutrition. This is the finding of a study in cancer cells and mice published August 10 in Nature. The study was led... Continue Reading

MM-398 Receives Fast Track Designation for Advanced Pancreatic Cancer (11-26-2014)

The U. S. Food and Drug Administration (FDA) has granted MM- 398 plus 5-fluorouracil (5-FU) and leucovorin a Fast Track designation as a second-line treatment for patients with metastatic pancreatic cancer, based on data from the phase III NAPOLI-1 study... Continue Reading

FDA Grants Orphan Drug Designation to Investigational Agent for Pancreatic Cancer (10-7-2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

Simtuzumab Fails to Improve Outcomes in Pancreatic Cancer (09-23-2014)

Pancreatic cancer is one of the deadliest forms of cancer. Each year, approximately 43,000 people are diagnosed with pancreatic cancer in the United States and close to 37,000 die from the disease. The disease is often diagnosed at an advanced stage,... Continue Reading

In Advanced Pancreatic Cancer, Eloxatin® with Folinic Acid and Fluorouracil May Improve Survival (07-10-2014)

In a Phase III study, the addition of the chemotherapy drug Eloxatin® (oxaliplatin) to the chemotherapy regimen of folinic acid and fluorouracil (5-FU) improved outcomes in patients with advanced pancreatic cancer that had progressed on Gemzar® (gemcitabine).... Continue Reading

Updated Analysis of the MPACT Study in Advanced Pancreatic Cancer Demonstrates Continued Improvement in Survival for Abraxane-based Chemotherapy (07-1-2014)

A follow up report on the results of the Metastatic Pancreatic Adenocarcinoma Clinical Trial (MPACT) study of Abraxane® (nab-paclitaxel) in combination with Gemzar® (gemcitabine) in previously untreated patients with metastatic pancreatic cancer... Continue Reading

Dual Vaccines Prolong Survival in Metastatic Pancreatic Cancer (02-5-2014)

The sequential delivery of two vaccines—GVAX and CRS-207—prolonged survival in patients with metastatic pancreatic cancer by about two months, according to the results of a study presented at the 2014 Gastorintestinal Cancers Symposium in San Francisco,... Continue Reading

Abraxane Plus Gemzar Improves Survival in Metastatic Pancreatic Cancer (12-25-2013)

Abraxane® (nab-paclitaxel) plus Gemzar® (gemcitabine) improved overall and progression-free survival in patients with previously untreated metastatic pancreatic cancer, according to the results of a study published in the New England Journal of Medicine. Pancreatic... Continue Reading

Study Evaluates Whole-brain Radiation Following Surgery or Radiosurgery in Cancer Spread to the Brain (11-16-2010)

Results from a randomized Phase III study indicate that whole-brain radiation therapy (WBRT) following removal of one to three brain metastases with surgery or radiosurgery does not improve overall survival or duration of functional independence but does... Continue Reading

Next Page »